S&P 500

5.277,51

0,80%

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Immix Biopharma Inc (IMMX)
Immix Biopharma Inc (IMMX) Notícias

IMMX

Immix Biopharma (IMMX)

Immix Biopharma Inc

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:IMMX

1 2 3 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
21/05/2024	17:05	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:IMMX	Immix Biopharma Inc
20/05/2024	18:27	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMMX	Immix Biopharma Inc
20/05/2024	18:27	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:IMMX	Immix Biopharma Inc
20/05/2024	18:25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMMX	Immix Biopharma Inc
09/05/2024	17:27	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IMMX	Immix Biopharma Inc
07/02/2024	19:15	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IMMX	Immix Biopharma Inc
28/11/2023	12:48	InvestorsHub NewsWire	Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing	NASDAQ:IMMX	Immix Biopharma Inc
09/11/2023	21:57	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:IMMX	Immix Biopharma Inc
29/09/2023	01:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:IMMX	Immix Biopharma Inc
25/09/2023	17:15	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:IMMX	Immix Biopharma Inc
30/08/2023	17:15	Edgar (US Regulatory)	Form SC 13D - General statement of acquisition of beneficial ownership	NASDAQ:IMMX	Immix Biopharma Inc
23/08/2023	17:26	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:IMMX	Immix Biopharma Inc
25/07/2023	09:42	GlobeNewswire Inc.	Immix Biopharma Subsidiary Nexcella Announces NXC-201 Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting	NASDAQ:IMMX	Immix Biopharma Inc
17/07/2023	10:37	GlobeNewswire Inc.	Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial	NASDAQ:IMMX	Immix Biopharma Inc
10/07/2023	10:47	GlobeNewswire Inc.	Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site	NASDAQ:IMMX	Immix Biopharma Inc
26/06/2023	10:49	GlobeNewswire Inc.	Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial	NASDAQ:IMMX	Immix Biopharma Inc
22/06/2023	10:53	GlobeNewswire Inc.	Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors	NASDAQ:IMMX	Immix Biopharma Inc
20/06/2023	10:45	GlobeNewswire Inc.	Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors	NASDAQ:IMMX	Immix Biopharma Inc
16/06/2023	10:43	GlobeNewswire Inc.	Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors	NASDAQ:IMMX	Immix Biopharma Inc
14/06/2023	08:30	GlobeNewswire Inc.	Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program	NASDAQ:IMMX	Immix Biopharma Inc
13/06/2023	18:27	Edgar (US Regulatory)	Securities Registration: Employee Benefit Plan (s-8)	NASDAQ:IMMX	Immix Biopharma Inc
12/06/2023	10:49	GlobeNewswire Inc.	Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors	NASDAQ:IMMX	Immix Biopharma Inc
08/06/2023	07:06	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:IMMX	Immix Biopharma Inc
26/05/2023	10:53	GlobeNewswire Inc.	Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site	NASDAQ:IMMX	Immix Biopharma Inc
21/05/2023	17:05	GlobeNewswire Inc.	Nexcella Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial	NASDAQ:IMMX	Immix Biopharma Inc
21/05/2023	17:00	GlobeNewswire Inc.	Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial	NASDAQ:IMMX	Immix Biopharma Inc
12/05/2023	18:01	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:IMMX	Immix Biopharma Inc
04/05/2023	13:30	GlobeNewswire Inc.	Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)	NASDAQ:IMMX	Immix Biopharma Inc
03/05/2023	09:00	GlobeNewswire Inc.	Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab	NASDAQ:IMMX	Immix Biopharma Inc
26/04/2023	18:30	GlobeNewswire Inc.	Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris	NASDAQ:IMMX	Immix Biopharma Inc